Trelegy Ellipta is a once-daily, single-inhaler triple therapy for the treatment of COPD [1]. It combines an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-agonist (LABA) [2].
What conditions does Trelegy treat?
Trelegy Ellipta is indicated for the maintenance treatment of patients with COPD [1]. This includes patients who are already receiving a combination of fluticasone furoate and vilanterol and umeclidinium bromide [2]. It is not intended for the relief of acute bronchospasm [1].
How does Trelegy work?
Trelegy Ellipta contains three active ingredients that work together to manage COPD symptoms. Fluticasone furoate is an inhaled corticosteroid that reduces inflammation in the airways. Umeclidinium bromide is a long-acting muscarinic antagonist that helps to relax the muscles around the airways, making breathing easier. Vilanterol is a long-acting beta2-agonist that also helps to relax the muscles in the airways [2]. By combining these three mechanisms, Trelegy helps to improve lung function and reduce the frequency of COPD exacerbations [1].
What are the potential side effects of Trelegy?
The most common side effects reported with Trelegy Ellipta include nasopharyngitis, headache, and influenza [1]. Other potential side effects can include pneumonia, bronchitis, oral thrush, and upper respiratory tract infections [2]. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
What is the difference between Trelegy and other COPD inhalers?
Trelegy Ellipta is a triple therapy inhaler, meaning it contains three different medications in a single device [2]. Many other COPD inhalers are dual therapies, containing only two medications, such as an ICS/LABA or LAMA/LABA combination [3]. The triple therapy approach in Trelegy aims to provide comprehensive symptom control and reduce exacerbations in certain COPD patients [1].
When does Trelegy's patent expire?
Information on specific patent expiry dates for Trelegy Ellipta can be found on patent tracking websites like DrugPatentWatch.com [4]. These dates are crucial for understanding when generic versions of the medication may become available.
Who manufactures Trelegy?
Trelegy Ellipta is manufactured by GlaxoSmithKline (GSK) [1].
What is the cost of Trelegy?
The cost of Trelegy Ellipta can vary depending on insurance coverage, pharmacy, and geographic location. Patients often utilize manufacturer coupons or patient assistance programs to help manage costs [4].
---
Sources:
[1] https://www.trelegy.com/
[2] https://www.gsksource.com/us/products/trelegy-ellipta
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580757/
[4] https://drugpatentwatch.com/